Eldred-Evans David, Sahai Arun
Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK MRC Centre for Transplantation, NIHR Biomedical Research Centre, King's College London and Guy's Hospital, London, UK.
MRC Centre for Transplantation, NIHR Biomedical Research Centre, King's College London and Guy's Hospital, London SE1 9RT, UK.
Ther Adv Urol. 2017 Jan;9(1):3-10. doi: 10.1177/1756287216672180. Epub 2016 Oct 19.
Botulinum toxin A (BoNT-A) has become an important therapeutic tool in the management of refractory overactive bladder (OAB). Over the last decade, there have been growing numbers of patients receiving repeat injections and these outcomes have begun to be reported in large, high-quality cohorts. This article reviews the current evidence for the medium- to long-term use of BoNT-A in adults with idiopathic detrusor overactivity (IDO) receiving repeat injections. We find that medium-term outcomes are encouraging but long-term outcomes are not as extensively reported. There is high-quality evidence that efficacy following the first injection persists across multiple treatment cycles. There are no additional safety concerns from repeat injections up to six treatment cycles. However, there is a need for further data to confirm the efficacy and safety of BoNT-A beyond the follow-up period in the current literature.
肉毒杆菌毒素A（BoNT-A）已成为治疗难治性膀胱过度活动症（OAB）的重要治疗工具。在过去十年中，接受重复注射的患者数量不断增加，这些结果已开始在大型高质量队列中得到报道。本文综述了目前关于接受重复注射的特发性逼尿肌过度活动症（IDO）成年患者中长期使用BoNT-A的证据。我们发现中期结果令人鼓舞，但长期结果的报道并不广泛。有高质量证据表明首次注射后的疗效在多个治疗周期中持续存在。重复注射多达六个治疗周期没有额外的安全问题。然而，需要进一步的数据来证实当前文献中随访期之外BoNT-A的疗效和安全性。
